<DOC>
	<DOCNO>NCT00216177</DOCNO>
	<brief_summary>The purpose study establish whether RA patient moderate severe disease activity unsustainable response infliximab 3 mg/kg every 8 week well efficacy adalimumab 40 mg s.c. eow compare infliximab 3 mg/kg i.v . every 6 week .</brief_summary>
	<brief_title>Comparison Adalimumab Infliximab Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>ACR criterion fulfil , DAS283 ( CRP &gt; 3.2 &gt; 6 month prior treatment infliximab 3 mg/kg i.v . every 8 week initial response Fading clinical response infliximab Negative pregnancy test ( woman childbearing potential ) Use reliable method contraception ( woman childbearing potential ) Informed consent Age le 18 year Lack cooperability Positive serology hepatitis B C History positive HIV status History TB untreated latent TB Histoplasmosis Listeriosis Pregnancy breastfeed Persistent recurrent infection History cancer Uncontrolled diabetes Ischaemic heart disease Congestive heart failure ( NYHA 34 ) Active inflammatory bowel disease Recent stroke ( within 3 month ) History current inflammatory joint disease RA Previous diagnosis sign central nervous system demyelinate disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>